Company Description
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA).
It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratory syncytial virus, rotavirus, malaria, and universal influenza.
The company also develops RNA-based cancer therapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck.
CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.
| Country | Germany |
| Founded | 2000 |
| IPO Date | Aug 14, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 904 |
| CEO | Dr. Alexander Zehnder M.B.A., M.D. |
Contact Details
Address: Paul-ehrlich-strabe 15 Tubingen Baden-wurttemberg, 2M 72076 Germany | |
| Phone | 49 7071 9883 0 |
| Website | curevac.com |
Stock Details
| Ticker Symbol | CVAC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001809122 |
| CUSIP Number | N2451R105 |
| ISIN Number | NL0015436031 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Pierre Kemula B.Sc. | MD, Chief Financial Officer and Member of Management Board |
| Dr. Malte Greune Ph.D. | Chief Operating Officer, Member of Management Board and MD |
| Dr. Ulrike Gnad-Vogt M.D., Ph.D. | Senior Vice President and Area Head of Oncology |
| Dr. Alexander Zehnder M.B.A., M.D. | Chief Executive Officer, MD and Member of Management Board |
| Dr. Myriam Mendila M.D. | Chief Development Officer, MD and Member of the Management Board |
| Dr. Sarah Fakih | Vice President Corporate Communications and Investor Relations |
| Marco Rau L.L.M., Ph.D. | General Counsel |
| Thorsten Schuller | Head of Corporate Communications |
| Slavica Stevanovic-Heck | Head of Human Resources |
| Dr. Patrick Baumhof | Senior Vice President of Technology |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 16, 2024 | 6-K | Report of foreign issuer |
| Apr 12, 2024 | 144 | Filing |
| Apr 4, 2024 | 6-K | Report of foreign issuer |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 6, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 17, 2024 | 6-K | Report of foreign issuer |
| Jan 5, 2024 | 6-K | Report of foreign issuer |
| Jan 5, 2024 | 144 | Filing |
| Jan 5, 2024 | 144 | Filing |
| Jan 5, 2024 | 144 | Filing |